Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W9JC
|
||||
| Former ID |
DNC013509
|
||||
| Drug Name |
1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [529193] | ||
| Formula |
C20H28N2O2
|
||||
| Canonical SMILES |
CCCCCCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
|
||||
| InChI |
1S/C20H28N2O2/c1-2-3-4-5-6-7-8-9-10-14-18(23)20-22-16-19(24-20)17-13-11-12-15-21-17/h11-13,15-16H,2-10,14H2,1H3
|
||||
| InChIKey |
VESZWTBYTDWAEO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Fatty-acid amide hydrolase | Target Info | Inhibitor | [529193] | |
| BioCyc Pathway | Anandamide degradation | ||||
| KEGG Pathway | Retrograde endocannabinoid signaling | ||||
| PANTHER Pathway | Anandamide degradation | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.